Skip to main content
SpringerLink
Log in

Interleukin 27 is up-regulated in patients with active inflammatory bowel disease

  • Original Article
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

The aim of the study was to characterize and quantify tissue gene and protein expression of IL-27 in ulcerative colitis (UC) and Crohn’s disease (CD) patients. This is an observational and cross-sectional study. Fifty-four patients with IBD were studied: 27 active UC, 12 inactive UC, 10 active CD, and 5 inactive CD. All patients belonged to the Inflammatory Bowel Disease Clinic at the Instituto Nacional de Ciencias Médicas y Nutrición. We found that IL-27 gene expression was significantly higher in active UC versus inactive UC group (P = 0.015). The IL-27 mRNA expression was increased in patients with active CD compared with inactive CD disease (P = 0.035). The percentage of IL-27 immunoreactive cells was higher in active UC versus active CD patients and non-inflamed tissue controls. The IL-27 was significantly elevated in active UC and CD patients, and it was associated with disease severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

IBD:

Inflammatory bowel disease

aUC:

Active ulcerative colitis

aCD:

Active Crohn’s disease

HD:

Healthy donors

cDNA:

Complementary DNA

dNTPs:

Deoxyribonucleotide triphosphate

AP:

Alkaline phosphatase

PCR:

Polymerase chain reaction

RT:

Reverse transcription

RT-PCR:

Real-time polymerase chain reaction

SD:

Standard deviation

SEM:

Standard error of the mean

References

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–29.

    Article  CAS  PubMed  Google Scholar 

  2. Fonseca-Camarillo G, Yamamoto-Furusho JK. Interleukins involved in inflammatory bowel disease as new therapeutic targets. Curr Immunol Rev. 2013;9(2):86–92.

    Article  CAS  Google Scholar 

  3. Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol. 2010;7(2):110–7.

    Article  PubMed  Google Scholar 

  4. Boulay JL, O’Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 2003;19(2):159–63.

    Article  CAS  PubMed  Google Scholar 

  5. Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004;173(2):715–20.

    Article  CAS  PubMed  Google Scholar 

  6. Murakami M, Kamimura D, Hirano T. New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27. Growth Factors. 2004;22(2):75–7.

    Article  CAS  PubMed  Google Scholar 

  7. Hölscher C. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol. 2004;193(1):1–17.

    Article  PubMed  Google Scholar 

  8. Yoh Matsumoto. Is interleukin-27 a real candidate for immunotherapies of multiple sclerosis? Clin Exp Neuroimmunol. 2013;4(1):7–9.

    Article  Google Scholar 

  9. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G568–76.

    Article  CAS  PubMed  Google Scholar 

  10. Sutherland LR, Martin F, Greer Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-aminosalicylicacid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894–8.

    Article  CAS  PubMed  Google Scholar 

  11. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, Vatn MH, Moum B. Ulcerative colitis and clinical course: results of a 5-year population based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.

    Article  PubMed  Google Scholar 

  12. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1(8167):514.

    Article  CAS  PubMed  Google Scholar 

  13. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94(6):1383–9.

    Article  CAS  PubMed  Google Scholar 

  14. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, Wu Y, Mayo L, Ben-Hamo R, Efroni S, Kuchr. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol. 2013;14(10):1054–1063.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wynick C, Petes C, Gee K. Interleukin-27 mediates inflammation during chronic disease. J Interferon Cytokine Res. 2014;34(10):741–9.

    Article  CAS  PubMed  Google Scholar 

  16. Visperas A, Do JS, Bulek K, Li X, Min B. IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol. 2014;7(3):625–33.

    Article  CAS  PubMed  Google Scholar 

  17. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11(1):16–23.

    Article  PubMed  Google Scholar 

  18. Yamamoto-Furusho JK, Posadas-Sánchez R, Alvarez-León E, Vargas-Alarcón G. Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. Immunol Lett. 2016;172:79–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a research Grant of CONACYT (Mexico) No. 178925.

Author information

Author notes

    Authors and Affiliations

    1. Department of Gastroenterology, Inflammatory Bowel Disease Clinic, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Vasco de Quiroga #15, Col. Belisario Domínguez Sección XVI, 14080, Mexico City, Mexico

      Gabriela Fonseca Camarillo & Jesús K. Yamamoto-Furusho

    2. Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Vasco de Quiroga #15, Col. Belisario Domínguez Sección XVI, 14080, Mexico City, Mexico

      Janette Furuzawa Carballeda

    Authors
    1. Janette Furuzawa Carballeda
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Gabriela Fonseca Camarillo
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Jesús K. Yamamoto-Furusho
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Jesús K. Yamamoto-Furusho.

    Ethics declarations

    Conflict of interest

    The authors declare no commercial or financial conflict of interest.

    Additional information

    Janette Furuzawa Carballeda and Gabriela Fonseca Camarillo have contributed equally to this manuscript.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Furuzawa Carballeda, J., Fonseca Camarillo, G. & Yamamoto-Furusho, J.K. Interleukin 27 is up-regulated in patients with active inflammatory bowel disease. Immunol Res 64, 901–907 (2016). https://doi.org/10.1007/s12026-016-8804-z

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12026-016-8804-z

    Keywords

    Search

    Navigation